No Data
SAAF Holdings Completes Acquisition, Cancellation of Stock Acquisition Rights
DWTI, Architects SJ and others.
＜1447＞ Acquisition and cancellation of all remaining subscription rights of the 4th series (with exercise price adjustment clause) of SAAFD. ＜3557＞ Large exercise of the 9th subscription rights (with exercise price adjustment clause) of U&C from the 4th, number of shares delivered, 0.07 million, 2000 shares. ＜4576＞ Approval obtained in Thailand for the glaucoma and ocular hypertension treatment "Grau Alpha combination eye drops (domestic product name)" of DWTI. ＜4586＞ Termination of joint research contract with Medrec Fanpepp. ＜4881＞ Soleasia's downward revision, current period operations.
DWTI, Anges and others [Emerging Markets press release]
Acquired and canceled all of the remaining 4th subscription rights (with exercise price adjustment clause) of ＜1447＞SAAFHHD. Terminated capital and business alliance with ＜3224＞G Oyster Hanwa Trading Company. Completed acquisition of treasury stock for ＜3646＞Ekitan. Entered into a contract regarding expanded newborn screening tests in Nagano Prefecture with Nagano Children's Hospital for ＜4563＞Anges. Patent examination for glaucoma treatment agent "H-1337" (South Korea) for ＜4576＞DWTI. Oncolytic virus from ＜4588＞Oncolis Bio.
SAAF Holdings Secures 1.8 Billion Yen Syndicated Loan for U-Shin Acquisition
SAAF Holdings to Sell San-Ai-Home to Grandes
SAAF Holdings Transfers Subsidiary to GRANDES